Axsome Therapeutics reported strong sales uptake of its drugs Auvelity and Sunosi in the US.
4 reports, 3 independent
Updated Aug 11
Gone quiet
Reached 3 outlets in its first 24 hours
- Reports
- 4
- Developments
- 3
- Repetition
- 25%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Axsome Therapeutics reported strong sales uptake of its drugs Auvelity and Sunosi in the US.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.Axsome Therapeutics reported strong sales uptake of Auvelity and Sunosi in the US.1 source
Axsome Therapeutics successfully launched SYMBRAVO into the acute migraine market.1 source
FDA approved Auvelity and Axsome completed the acquisition of Sunosi.1 source
Keep exploring
The entities involved
-
Axsome Therapeutics
American biopharmaceutical company
Nothing else this week.
Coverage
Newest first; wire copies grouped- ZacksWhy Is Axsome (AXSM) Up 19.2% Since Last Earnings Report? It has been about a month since the last earnings report for Axsome Therapeutics (AXSM). Shares have added about 19.2% in that time frame, ou
- GuruFocus.comAxsome Therapeutics Inc (AXSM) Q2 2025 Earnings Call Highlights: Robust Revenue Growth and ... Total Revenue: $150 million for the quarter, a 72% year-over-year increase and a 24% quarter-over-quarte
- Barchart2 Growth Stocks Wall Street Predicts Will Soar 74% to 159% In the highly competitive biotech industry, only a few standout companies attract Wall Street’s attention. Among them, two high-growth biote